Form 8-K · Current Report · Filed 2025-09-11
West Pharmaceutical Services Announces Senior Executive Departure
West Pharmaceutical Services, Inc. announced today, September 11, 2025, that Kimberly Banks MacKay, Senior Vice President, General Counsel, and Corporate Secretary, will be leaving the Company. The departure is part of a planned transition ending by December 31, 2025, ensuring continuity of operations. Ms. MacKay will continue in her current role until her departure, during which the Company will discuss and plan for her successor. The Company thanks Ms. MacKay for her service and contributions.
- Filer
- West Pharmaceutical Services Inc. WST · NYSE
- Filed
- Accession
- 0000105770-25-000083
- CIK
- 0000105770
- Signal
- High impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Market reaction
Close before filing
$255.22
Next session
-0.7%
Since filing
+33.6%
Latest close
$340.96
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from WST reporting the same item, with the next session's move:
About West Pharmaceutical Services Inc.
West Pharmaceutical Services Inc. is a leading global provider of innovative solutions for injectable drug administration. The company specializes in designing and manufacturing packaging and delivery systems specifically for pharmaceuticals, biologics, and vaccines. West Pharmaceutical Services plays a crucial role in ensuring the safety and efficiency of drug delivery through its products, which include stoppers, seals, containers, and pre-fillable syringe systems. Catering to a diverse range of healthcare and pharmaceutical clients, the company's offerings are integral in the development and distribution of injectable therapies across various therapeutic categories, including oncology, diabetes, and infectious diseases. As a partner to some of the world's leading pharmaceutical companies, West Pharmaceutical Services contributes significantly to advancements in medical treatments and healthcare technologies globally. Its commitment to quality and innovation underscores its importance in the pharmaceutical supply chain and enhances drug efficacy, ultimately impacting patient care and treatment outcomes.
Never miss another WST filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.